A RANDOMIZED, DOUBLE-BLIND, EVENT-DRIVEN, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFECTS OF CANAGLIFLOZIN ON RENAL AND CARDIOVASCULAR OUTCOMES IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY (CREDENCE TRIAL)
Principal Investigator(s)
Hura,Claudia E.
Funded by
JANSSEN PHARMACEUTICA RESEARCH FOUNDATIO
Research Start Date
Status
Active